Results 41 to 50 of about 89,117 (340)
6'-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding [PDF]
, 2020 Raloxifene (RAL) is an FDA-approved drug used to treat osteoporosis in postmenopausal women. RAL suppresses bone loss primarily through its role as a selective estrogen receptor modulator (SERM).
Allen, Matthew R. +9 more
core +1 more source
Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial [PDF]
, 2018 Background Tiludronate and clodronate are FDA-approved bisphosphonate drug therapies for navicular disease in horses. Although clinical studies have determined their ability to reduce lameness associated with skeletal disorders in horses, data regarding
Gillett, Ashley N. +3 more
core +1 more source
BMC Musculoskeletal Disorders, 2009 Background Occurrence of atrial fibrillation (AF) amongst bisphosphonate users has been increasingly reported but results are conflicting. We performed a Bayesian meta-analysis to address the possible association between the occurrence of AF and ...
Cheak Alicia +4 more
doaj +1 more source
eLife, 2022 Bisphosphonate-related osteonecrosis of the jaw (BRONJ) presents as a morbid jawbone lesion in patients exposed to a nitrogen-containing bisphosphonate (N-BP). Although it is rare, BRONJ has caused apprehension among patients and healthcare providers and
Hiroko Okawa +13 more
doaj +1 more source
Prevention of osteoporotic refractures in regional Australia [PDF]
, 2017 Objective: Clinical guidelines recommend that patients who sustain a minimal trauma fracture (MTF) should receive a bone mineral density (BMD) scan and bisphosphonate (or equivalent) therapy if diagnosed with osteoporosis.
Davidson, E +4 more
core +2 more sources
Bisphosphonate-associated osteonecrosis of the jaw in rheumatology: a sistematic review
Reumatismo, 2011 Osteonecrosis of the jaw (ONJ) is a well-known devastating side effect of parenteral bisphosphonate therapy for cancer. Several ONJ cases have been reported in patients taking oral bisphosphonates for osteoporosis or Paget’s disease.
F. Capsoni
doaj +1 more source
PLoS ONE, 2020 BackgroundGiving patients anti-osteoporotic agents peri-operatively is a well-accepted strategy to increase fusion rate and prevent complications. The purpose of this study was to investigate effectiveness of teriparatide and bisphosphonate on fusion ...
Shih-Hao Cheng +3 more
doaj +1 more source
Etidronate as A Weak Chelating Agent on Root Canal Dentin: An Update Review [PDF]
Journal of Clinical and Diagnostic Research, 2017 Successful root canal treatment depends on proper biomechanical cleaning and shaping of root canal system followed by threedimensional obturation. Irrigation solutions and chelating agents are used during root canal treatment to assist in smear layer ...
Samah Samir Bedir +2 more
doaj +1 more source
Trauma Case Reports, 2020 Osteoporotic patients being treated with bisphosphonates present an interesting dilemma when removing hardware such as dynamic hip screws “DHS”. In this paper, we describe the case of a 66-year-old osteoporotic patient who was placed on long term ...
Bardia Barimani +4 more
doaj +1 more source
Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug
Scientific Reports, 2017 Bisphosphonates have benefits in breast cancer and multiple myeloma patients and have been used with adoptive immunotherapy with γδ T cells expressing Vγ2 Vδ2 TCRs. Although treatment with γδ T cells is safe, it has shown limited efficacy.
Yoshimasa Tanaka +9 more
semanticscholar +1 more source